Blackhawk Growth Corp Advances in Asthmatic AI Clinical Trials

Blackhawk Growth Corp, listed as BLR on the Canadian Stock Exchange and 0JJ in Frankfurt, has announced significant progress in its Asthmatic AI venture. This technology, developed by the Hardenbrook portfolio company, has completed trials with 50 participants and is expanding to include an additional 250. Asthmatic AI aims to predict asthma attacks, enhancing clinical management of the condition.

The technology utilizes wearable devices and a smartphone application to monitor various biophysical and environmental indicators, predicting asthma attacks before they occur. By analyzing data such as heart rate and environmental factors, Asthmatic AI provides a proactive approach to asthma care, potentially reducing the global health burden significantly.

Blackhawk, through its association with Hardenbrook Group, continues to focus on health tech AI, preparing to launch more innovations under Life AI Corp, which will soon be publicly listed. This includes technologies like Mood AI and Autism AI, aimed at addressing various health challenges through advanced AI solutions.